Marinus Pharmaceuticals Inc (NASDAQ:MRNS) major shareholder Bain Capital Life Sciences Inv sold 822,547 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $8.10, for a total value of $6,662,630.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Bain Capital Life Sciences Inv also recently made the following trade(s):
- On Tuesday, December 19th, Bain Capital Life Sciences Inv sold 1,272,547 shares of Marinus Pharmaceuticals stock. The stock was sold at an average price of $7.88, for a total value of $10,027,670.36.
Marinus Pharmaceuticals Inc (NASDAQ MRNS) opened at $7.85 on Friday. Marinus Pharmaceuticals Inc has a twelve month low of $0.83 and a twelve month high of $9.87.
A number of brokerages recently weighed in on MRNS. Laidlaw began coverage on Marinus Pharmaceuticals in a report on Thursday, December 14th. They set a “buy” rating and a $18.00 price objective on the stock. ValuEngine lowered Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub lowered Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Finally, JMP Securities reaffirmed an “outperform” rating and set a $11.00 price objective (up previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Tuesday, September 12th.
Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp purchased a new stake in Marinus Pharmaceuticals during the third quarter worth $128,000. Citadel Advisors LLC boosted its position in Marinus Pharmaceuticals by 327.8% during the third quarter. Citadel Advisors LLC now owns 51,383 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 39,371 shares in the last quarter. Susquehanna International Group LLP purchased a new stake in Marinus Pharmaceuticals during the third quarter worth $503,000. EAM Investors LLC purchased a new stake in Marinus Pharmaceuticals during the third quarter worth $554,000. Finally, Iguana Healthcare Management LLC purchased a new stake in Marinus Pharmaceuticals during the third quarter worth $1,027,000. Institutional investors own 49.77% of the company’s stock.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.